Search

Displaying results 2981 - 2990 of 10000 in total
  1. Drug

    Thymalfasin

    go.drugbank.com/drugs/DB04900
    Investigational

    Thymosin alpha 1 is an acetylated polypeptide. Thymosin alpha 1 is now approved in 35 developing countries for the treatment of Hepatitis B and C. … It is also used to boost the immune response in the treatment of other diseases.

  2. Drug

    Lymecycline

    go.drugbank.com/drugs/DB00256
    ApprovedInvestigationalWithdrawn

    [A203255] Lymecycline was initially discovered in 1961. It is marketed by Galderma and used in the UK as well as New Zealand in addition to other countries. … Lymecycline is not marketed in the USA, however, equivalent drugs are available, such as minocycline and [tetracycline].[A19429,L13880]

    Synonyms: N-Lysinomethyltetracycline, (+)-N-(5-Amino-5-carboxypentylaminomethyl)-4-dimethylamino-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxonaphthacene-2-carboxamide
  3. Drug

    EP-1043

    go.drugbank.com/drugs/DB06118
    Experimental

    EP-1043 is an epitope-based recombinant protein vaccine designed to induce HIV-1 specific helper T-lymphocyte (HTL) responses. … The epitopes included in the vaccine were selected using Epitope Identification System (EIS) and each of them is predicted to be recognized in the majority of the prospective patient population.

  4. Drug

    Pretomanid

    go.drugbank.com/drugs/DB05154
    ApprovedInvestigational

    It was the first TB drug developed by a nonprofit organization, known as TB Alliance, and was granted FDA approval on August 14, 2019. … [A182915] Pretomanid is an antimycobacterial agent that is administered with [Bedaquiline] and [Linezolid] to treat resistant forms of pulmonary TB.

  5. Drug

    Favipiravir

    go.drugbank.com/drugs/DB12466
    ApprovedInvestigational

    Discovered by Toyama Chemical Co., Ltd. in Japan, favipiravir is a modified pyrazine analog that was initially approved for therapeutic use in resistant cases of influenza. … [A191688,A191772,A191775] Not only does favipiravir inhibit replication of influenza A and B, but the drug has shown promise in the treatment of avian influenza, and may be an alternative option for

  6. Drug

    Brivaracetam

    go.drugbank.com/drugs/DB05541
    ApprovedInvestigational

    Briviact received FDA approval on February 19, 2016 [L760]. … Brivaracetam is a racetam derivative of levetiracetam used in the treatment of partial-onset seizures. Brivaracetam binds SV2A with 20 times higher affinity than levetiracetam [A19184].

  7. Drug

    Revakinagene taroretcel

    go.drugbank.com/drugs/DB05344
    ApprovedInvestigational

    [A265115] On March 6, 2025, FDA approved revakinagene taroretcel for the treatment of idiopathic macular telangiectasia type 2. … [L52540] It has also been investigated in glaucoma,[A265115] retinitis pigmentosa (RP), and age-related macular degeneration.[A265125]

    Synonyms: An allogeneic human adult retinal pigment epithelial (RPE) cell line stably transfected with a plasmid
  8. Drug

    Ensitrelvir

    go.drugbank.com/drugs/DB18834
    ApprovedInvestigational

    Ensitrelvir is under investigation in clinical trial NCT05605093 (Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor (Ensitrelvir)).

  9. Drug

    Tebipenem pivoxil

    go.drugbank.com/drugs/DB16840
    Approved

    [L57980] Tebipenem pivoxil is the first oral carbapenem approved in the United States, creating an outpatient option for patients who have limited or no alternative oral therapy. … [L57979] The FDA approved tebipenem pivoxil on June 17, 2026, for complicated urinary tract infections including pyelonephritis caused by designated susceptible organisms in adult patients who have

  10. Drug

    Ferumoxides

    go.drugbank.com/drugs/DB09508
    Approved

    Categories: Compounds used in a research, industrial, or household setting